Acadia adds late-stage development candidate for Prader-Willi syndrome to portfolio
Dr_Microbe/iStock via Getty Images
- Acadia Pharmaceuticals (NASDAQ:ACAD) on Tuesday said it had added a new late-stage developmental candidate called ACP-101 to its rare disease portfolio.
- ACAD stock was down 2.2% to $24.49 in extended trading. It earlier closed +1.7% at $25.03.
- ACP-101 is an intranasal version of carbetocin, which is a selective oxytocin-receptor agonist for the treatment of hyperphagia (a feeling of extreme, insatiable hunger) in the genetic disorder Prader-Willi syndrome.
- ACAD had acquired the worldwide rights to make and sell ACP-101 with the acquisition of Levo Therapeutics in June last year.
- The company added that it had recently met with the U.S. Food and Drug Administration about a planned phase 3 study with ACP-101, which is anticipated to start in Q4 2023.